Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.
Gabriella MaioliRoberto Felice CaporaliEnnio Giulio FavalliPublished in: Expert opinion on drug discovery (2022)
Results from clinical trials confirmed the efficacy and safety of sarilumab for the treatment of RA, similar to its precursor tocilizumab. Blocking IL-6 pathway results in comprehensive control of the disease, from both physician's and patient's perspective, and of RA comorbidities and extra-articular manifestations, which are largely IL-6 driven. Finally, the proven efficacy of sarilumab as monotherapy arises the drug as a required therapeutic alternative considering the large proportion of patients intolerant or inadequate to receive conventional synthetic disease-modifying drugs (csDMARDs).
Keyphrases
- rheumatoid arthritis
- clinical trial
- disease activity
- end stage renal disease
- combination therapy
- newly diagnosed
- primary care
- emergency department
- ejection fraction
- ankylosing spondylitis
- peritoneal dialysis
- case report
- randomized controlled trial
- high throughput
- systemic lupus erythematosus
- replacement therapy
- adverse drug
- double blind